Your browser is no longer supported. Please, upgrade your browser.
ETNB 89bio, Inc. monthly Stock Chart
89bio, Inc.
Index- P/E- EPS (ttm)-3.88 Insider Own0.57% Shs Outstand16.88M Perf Week5.04%
Market Cap510.41M Forward P/E- EPS next Y-3.88 Insider Trans- Shs Float7.60M Perf Month13.57%
Income-56.20M PEG- EPS next Q-0.87 Inst Own99.60% Short Float3.55% Perf Quarter-28.68%
Sales- P/S- EPS this Y-210.60% Inst Trans41.86% Short Ratio1.34 Perf Half Y11.94%
Book/sh12.67 P/B2.15 EPS next Y-24.40% ROA-46.50% Target Price- Perf Year-9.43%
Cash/sh11.72 P/C2.33 EPS next 5Y16.00% ROE-49.60% 52W Range14.00 - 47.25 Perf YTD3.77%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-42.27% Beta-
Dividend %- Quick Ratio23.60 Sales past 5Y- Gross Margin- 52W Low94.86% ATR1.24
Employees25 Current Ratio23.60 Sales Q/Q- Oper. Margin- RSI (14)59.00 Volatility3.87% 5.08%
OptionableYes Debt/Eq0.00 EPS Q/Q44.30% Profit Margin- Rel Volume0.45 Prev Close27.04
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume200.79K Price27.28
Recom1.40 SMA206.86% SMA509.29% SMA200-2.25% Volume89,539 Change0.89%
Oct-19-20Initiated Raymond James Strong Buy $65
Sep-25-20Upgrade BofA Securities Neutral → Buy $37 → $43
Jul-31-20Initiated Piper Sandler Overweight $54
Jul-23-20Initiated BTIG Research Buy
Jul-07-20Initiated Chardan Capital Markets Buy $58
Dec-09-19Initiated SVB Leerink Outperform
Dec-09-19Initiated RBC Capital Mkts Outperform
Dec-09-19Initiated Oppenheimer Outperform
Dec-09-19Initiated BofA/Merrill Neutral
Nov-24-20 08:00AM  
Nov-13-20 08:00AM  
Nov-10-20 04:02PM  
Nov-08-20 09:29AM  
Nov-02-20 08:00AM  
Sep-28-20 05:18PM  
Sep-23-20 07:00AM  
Sep-16-20 08:51PM  
Sep-14-20 05:21PM  
Sep-13-20 07:53PM  
Sep-03-20 08:30AM  
Aug-13-20 04:05PM  
Aug-11-20 08:32AM  
Aug-10-20 12:15PM  
Aug-03-20 04:05PM  
Jul-24-20 06:12PM  
Jul-13-20 10:18AM  
Jul-10-20 08:26AM  
Jul-07-20 09:30PM  
Jul-06-20 06:30AM  
Jun-04-20 08:00AM  
May-27-20 05:26PM  
May-13-20 04:05PM  
May-08-20 07:30AM  
Apr-13-20 08:30AM  
Mar-25-20 04:05PM  
Mar-18-20 04:05PM  
Feb-21-20 04:05PM  
Feb-11-20 06:43AM  
Dec-18-19 04:05PM  
Nov-13-19 04:02PM  
Nov-11-19 09:25AM  
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Le-Nguyen QuocSee RemarksNov 16Option Exercise3.114,54814,1444,548Nov 18 04:00 PM
Waisbourd RamCOO and Chief Business OfficerNov 16Option Exercise1.937,00013,5107,000Nov 18 04:00 PM
Waisbourd RamCOO and Chief Business OfficerNov 16Sale27.397,000191,7300Nov 18 04:00 PM
Le-Nguyen QuocSee RemarksNov 16Sale28.114,548127,8440Nov 18 04:00 PM
ORBIMED ADVISORS LLCDirectorSep 21Sale28.00275,0007,700,0001,864,721Sep 23 05:09 PM
Naschitz AnatDirectorSep 21Sale28.00275,0007,700,0001,864,721Sep 23 05:04 PM
RA CAPITAL MANAGEMENT, L.P.DirectorSep 17Buy28.001,300,00036,400,0004,736,214Sep 21 04:30 PM
Longitude Capital Partners III10% OwnerJul 10Buy27.50109,0902,999,9752,600,877Jul 14 08:11 PM
Grunberg GregoryDirectorJul 10Buy27.50109,0902,999,9752,600,877Jul 14 08:08 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJul 08Buy27.50275,0007,562,5003,436,214Jul 10 04:32 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.